Avutometinib is a medication being studied for its potential to treat recurrent low-grade serous ovarian cancer. It works by inhibiting certain proteins involved in cell growth, specifically targeting RAF and MEK pathways. This medication is being tested both on its own and in combination with another drug to determine its effectiveness.

Defactinib is another medication involved in this study. It is known as a FAK inhibitor, which means it targets a protein called FAK that is involved in cancer cell survival and spread. In this trial, defactinib is being used in combination with avutometinib to see if the two drugs together can more effectively treat the cancer compared to using avutometinib alone.

Recurrent Low-Grade Serous Ovarian Cancer – This is a type of ovarian cancer characterized by the presence of slow-growing cancer cells in the ovaries. It is known for its tendency to recur after initial treatment, which means the cancer can come back even after it has been treated. The cancer cells in this type are less aggressive compared to high-grade serous ovarian cancer, but they can still spread to other parts of the body over time. The progression of this disease is typically slower, and it may not cause symptoms immediately. As the cancer progresses, it can lead to symptoms such as abdominal pain, bloating, and changes in bowel habits. The disease is often diagnosed at a later stage due to its subtle symptoms.